The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial - PubMed (original) (raw)
Clinical Trial
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial
Karen G Chee et al. Clin Genitourin Cancer. 2007 Dec.
Abstract
Background: Perifosine is an oral alkylphospholipid that inhibits cancer cell growth through decreased Akt phosphorylation. We conducted a phase II trial of perifosine in patients with biochemically recurrent, hormone-sensitive prostate cancer.
Patients and methods: Eligible patients had histologically confirmed prostate cancer, previous prostatectomy and/or radiation therapy, and rising prostate-specific antigen (PSA) without radiographic evidence of metastasis. Previous androgen deprivation therapy < 9 months in duration (completed >or= 1 year before registration) was allowed. The primary endpoint was PSA response, defined as a decrease by >or= 50% from the pretreatment value. Treatment was composed of a loading dose of perifosine 900 mg orally on day 1, then 100 mg daily starting 24 hours later.
Results: Of 25 patients, 24 were evaluable for response. After a median follow-up of 8 months, 5 patients (20%) had a reduction in serum PSA levels, but none met criteria for PSA response. Three patients immediately progressed with no response to therapy. Median progression-free survival was 6.64 months (range, 4.53-12.81 months). No change in the PSA doubling time (7 months) was observed before and after treatment initiation. Dose-limiting toxicities (all grade 3) included hyponatremia, arthritis, hyperuricemia, and photophobia.
Conclusion: Although well tolerated, perifosine did not meet prespecified PSA criteria for response as a single agent in biochemically recurrent prostate cancer. However, 20% of patients had evidence of PSA reduction, suggesting modest single-agent clinical activity. The role of perifosine in combination with androgen deprivation or chemotherapy is currently under investigation.
Similar articles
- Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial.
Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN Jr, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR. Cheung E, et al. Clin Genitourin Cancer. 2009 Jan;7(1):43-50. doi: 10.3816/CGC.2009.n.008. Clin Genitourin Cancer. 2009. PMID: 19213668 Clinical Trial. - Survival benefit for early hormone ablation in biochemically recurrent prostate cancer.
Tenenholz TC, Shields C, Ramesh VR, Tercilla O, Hagan MP. Tenenholz TC, et al. Urol Oncol. 2007 Mar-Apr;25(2):101-9. doi: 10.1016/j.urolonc.2006.03.002. Urol Oncol. 2007. PMID: 17349523 - Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Fujii Y, Kawakami S, Masuda H, Kobayashi T, Hyochi N, Kageyama Y, Kihara K. Fujii Y, et al. BJU Int. 2006 Jun;97(6):1184-9. doi: 10.1111/j.1464-410X.2006.06149.x. BJU Int. 2006. PMID: 16686709 - Perifosine--a new option in treatment of acute myeloid leukemia?
Krawczyk J, Keane N, Swords R, O'Dwyer M, Freeman CL, Giles FJ. Krawczyk J, et al. Expert Opin Investig Drugs. 2013 Oct;22(10):1315-27. doi: 10.1517/13543784.2013.826648. Epub 2013 Aug 9. Expert Opin Investig Drugs. 2013. PMID: 23931614 Review. - Perifosine: update on a novel Akt inhibitor.
Gills JJ, Dennis PA. Gills JJ, et al. Curr Oncol Rep. 2009 Mar;11(2):102-10. doi: 10.1007/s11912-009-0016-4. Curr Oncol Rep. 2009. PMID: 19216841 Free PMC article. Review.
Cited by
- Silencing APLNR enhances the radiosensitivity of prostate cancer by modulating the PI3K/AKT/mTOR signaling pathway.
Li P, Cui Y, Hu K, Wang X, Yu Y. Li P, et al. Clin Transl Oncol. 2024 Sep 10. doi: 10.1007/s12094-024-03692-1. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39251496 - Reciprocal negative feedback regulation of ATF6α and PTEN promotes prostate cancer progression.
Feng T, Zhao R, Zhang H, Sun F, Hu J, Wang M, Qi M, Liu L, Gao L, Xiao Y, Zhen J, Chen W, Wang L, Han B. Feng T, et al. Cell Mol Life Sci. 2023 Sep 16;80(10):292. doi: 10.1007/s00018-023-04940-3. Cell Mol Life Sci. 2023. PMID: 37715829 Free PMC article. - Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?
Patrikidou A, Zilli T, Baciarello G, Terisse S, Hamilou Z, Fizazi K. Patrikidou A, et al. Ther Adv Med Oncol. 2021 Oct 20;13:17588359211051870. doi: 10.1177/17588359211051870. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34707693 Free PMC article. Review. - Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies.
Bumbaca B, Li W. Bumbaca B, et al. Acta Pharm Sin B. 2018 Jul;8(4):518-529. doi: 10.1016/j.apsb.2018.04.007. Epub 2018 Apr 30. Acta Pharm Sin B. 2018. PMID: 30109177 Free PMC article. Review. - Recent Advances in Prostate Cancer Treatment and Drug Discovery.
Nevedomskaya E, Baumgart SJ, Haendler B. Nevedomskaya E, et al. Int J Mol Sci. 2018 May 4;19(5):1359. doi: 10.3390/ijms19051359. Int J Mol Sci. 2018. PMID: 29734647 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous